Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab

作者
Despoina Florou,Μαρία Κατσάρα,Jack Feehan,Efthimios Dardiotis,Vasso Apostolopoulos
出处
期刊:Brain Sciences [Multidisciplinary Digital Publishing Institute]
卷期号:10 (10): 758-758 被引量:93
标识
DOI:10.3390/brainsci10100758
摘要

Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder. However, newer evidence shows that B cells play a crucial role in the pathogenesis of MS via antigen-driven autoantibody responses and through the cross regulation of T-helper cells. As B cells express the surface molecule CD20 at all points of differentiation, it provides a specific target for monoclonal antibodies, and the development and clinical testing of anti-CD20 antibody treatments for MS have been successful. After some observations, some small clinical trials found positive effects for the first anti-CD20 therapeutic rituximab in MS; newer agents have been specifically evaluated, resulting in the development of ocrelizumab and ofatumumab. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, was approved in March 2017 by the Food and Drug Administration (FDA) and is also the first proven therapy to reduce disability progression in primary progressive MS. This is particularly significant considering that disease-modifying treatment options are few for both primary and secondary progressive MS. Ofatumumab, a fully human anti-CD20 monoclonal antibody, that binds a distinct epitope, has been further investigated in phase 3 trials for relapsing forms of MS. In this review, we discuss in detail these two anti-CD20 agents and their advent for treatment of MS.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wjjoo发布了新的文献求助10
刚刚
深情安青的应助被sherry采纳,获得10
1秒前
1秒前
Yeal发布了新的文献求助10
1秒前
1秒前
动听绿茶完成签到,获得积分10
1秒前
2秒前
虚幻的便当完成签到,获得积分10
2秒前
优雅的幻然完成签到,获得积分10
2秒前
清脆慕山发布了新的文献求助10
2秒前
林l完成签到,获得积分10
2秒前
2秒前
在水一方的应助被ke采纳,获得10
2秒前
海派Hi发布了新的文献求助10
3秒前
bbh发布了新的文献求助10
3秒前
老詹头完成签到,获得积分10
3秒前
3秒前
Gmute发布了新的文献求助10
3秒前
潇洒红牛发布了新的文献求助10
4秒前
苏喜财的应助被王彬采纳,获得10
4秒前
tion66完成签到 ,获得积分10
4秒前
王文艺完成签到,获得积分10
4秒前
鱼憨儿发布了新的文献求助10
4秒前
4秒前
芝士就是力量完成签到,获得积分10
5秒前
束滟泽完成签到,获得积分10
5秒前
5秒前
斯文败类的应助被小黑米采纳,获得10
5秒前
zz完成签到,获得积分10
6秒前
小马甲的应助被祥瑞采纳,获得10
6秒前
6秒前
嘻嘻哈哈的应助被gxhjky采纳,获得10
6秒前
JamesPei的应助被地道的反差萌采纳,获得80
6秒前
王文艺发布了新的文献求助10
6秒前
怕黑的尔安完成签到,获得积分10
7秒前
WangC发布了新的文献求助10
7秒前
lll发布了新的文献求助10
7秒前
周如鑫完成签到,获得积分10
8秒前
南风完成签到,获得积分10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162816
求助须知:如何正确求助?哪些是违规求助? 9557103
关于积分的说明 21738393
捐赠科研通 7753330
什么是DOI,文献DOI怎么找? 3427963
关于科研通互助平台的介绍 2552742
邀请新用户注册赠送积分活动 2472556